Kelly Anne Newell

List of Publications by Year
in descending order

61	2,182	218677	233421
papers	citations	26 h-index	45 g-index

62	62	62	3314
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Molecular evidence of N-methyl-D-aspartate receptor hypofunction in schizophrenia. Molecular Psychiatry, 2013, 18, 1185-1192.	7.9	202
2	Increased cannabinoid receptor density in the posterior cingulate cortex in schizophrenia. Experimental Brain Research, 2006, 172, 556-560.	1.5	169
3	Galantamine improves cognition, hippocampal inflammation, and synaptic plasticity impairments induced by lipopolysaccharide in mice. Journal of Neuroinflammation, 2018, 15, 112.	7.2	160
4	Negativity towards negative results: a discussion of the disconnect between scientific worth and scientific culture. DMM Disease Models and Mechanisms, 2014, 7, 171-173.	2.4	152
5	Short- and long-term effects of antipsychotic drug treatment on weight gain and H1 receptor expression. Psychoneuroendocrinology, 2008, 33, 569-580.	2.7	89
6	The effects of maternal antidepressant use on offspring behaviour and brain development: Implications for risk of neurodevelopmental disorders. Neuroscience and Biobehavioral Reviews, 2017, 80, 743-765.	6.1	80
7	Alterations of muscarinic and GABA receptor binding in the posterior cingulate cortex in schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2007, 31, 225-233.	4.8	79
8	Metabotropic glutamate receptor 5 in the pathology and treatment of schizophrenia. Neuroscience and Biobehavioral Reviews, 2013, 37, 256-268.	6.1	75
9	High dose of simvastatin induces hyperlocomotive and anxiolytic-like activities: The association with the up-regulation of NMDA receptor binding in the rat brain. Experimental Neurology, 2009, 216, 132-138.	4.1	64
10	Molecular evidence of synaptic pathology in the CA1 region in schizophrenia. NPJ Schizophrenia, 2016, 2, 16022.	3.6	62
11	Metabotropic glutamate receptor mGluR2/3 and mGluR5 binding in the anterior cingulate cortex in psychotic and nonpsychotic depression, bipolar disorder and schizophrenia: implications for novel mGluR-based therapeutics. Journal of Psychiatry and Neuroscience, 2014, 39, 407-416.	2.4	60
12	Alterations of mGluR5 and its endogenous regulators Norbin, Tamalin and Preso1 in schizophrenia: towards a model of mGluR5 dysregulation. Acta Neuropathologica, 2015, 130, 119-129.	7.7	48
13	Tacrineâ€“Hydrogen Sulfide Donor Hybrid Ameliorates Cognitive Impairment in the Aluminum Chloride Mouse Model of Alzheimerâ€™s Disease. ACS Chemical Neuroscience, 2019, 10, 3500-3509.	3.5	47
14	Excitatory and inhibitory neurotransmission is chronically altered following perinatal NMDA receptor blockade. European Neuropsychopharmacology, 2009, 19, 256-265.	0.7	45
15	Dietary teasaponin ameliorates alteration of gut microbiota and cognitive decline in diet-induced obese mice. Scientific Reports, 2017, 7, 12203.	3.3	45
16	The kynurenine pathway in major depression: What we know and where to next. Neuroscience and Biobehavioral Reviews, 2021, 127, 917-927.	6.1	42
17	Reciprocal signalling between NR2 subunits of the NMDA receptor and neuregulin1 and their role in schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2011, 35, 896-904.	4.8	36
18	Shifting towards a model of mGluR5 dysregulation in schizophrenia: Consequences for future schizophrenia treatment. Neuropharmacology, 2017, 115, 73-91.	4.1	36

#	Article	IF	Citations
19	Perinatal phencyclidine treatment alters neuregulin 1/erbB4 expression and activation in later life. European Neuropsychopharmacology, 2012, 22, 356-363.	0.7	35
20	Novel implications of Lingo-1 and its signaling partners in schizophrenia. Translational Psychiatry, 2014, 4, e348-e348.	4.8	35
21	Ionotropic glutamate receptor binding in the posterior cingulate cortex in schizophrenia patients. NeuroReport, 2005, 16, 1363-1367.	1.2	34
22	A neuregulin 1 transmembrane domain mutation causes imbalanced glutamatergic and dopaminergic receptor expression in mice. Neuroscience, 2013, 248, 670-680.	2.3	34
23	Metabotropic glutamate receptor 5 binding and protein expression in schizophrenia and following antipsychotic drug treatment. Schizophrenia Research, 2013, 146, 170-176.	2.0	34
24	Effect of cannabidiol on endocannabinoid, glutamatergic and GABAergic signalling markers in male offspring of a maternal immune activation (poly I:C) model relevant to schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 95, 109666.	4.8	34
25	Short and long term changes in NMDA receptor binding in mouse brain following chronic phencyclidine treatment. Journal of Neural Transmission, 2007, 114, 995-1001.	2.8	32
26	Cannabidiol improves behavioural and neurochemical deficits in adult female offspring of the maternal immune activation (poly I:C) model of neurodevelopmental disorders. Brain, Behavior, and Immunity, 2019, 81, 574-587.	4.1	32
27	The Wistar-Kyoto rat model of endogenous depression: A tool for exploring treatment resistance with an urgent need to focus on sex differences. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2020, 101, 109908.	4.8	29
28	Density of metabotropic glutamate receptors 2 and 3 (mGluR2/3) in the dorsolateral prefrontal cortex does not differ with schizophrenia diagnosis but decreases with age. Schizophrenia Research, 2011, 128, 56-60.	2.0	28
29	Perinatal exposure to fluoxetine increases anxiety- and depressive-like behaviours and alters glutamatergic markers in the prefrontal cortex and hippocampus of male adolescent rats: A comparison between Sprague-Dawley rats and the Wistar-Kyoto rat model of depression. Journal of Psychopharmacology, 2019, 33, 230-243.	4.0	28
30	Metabotropic glutamate receptor 5, and its trafficking molecules Norbin and Tamalin, are increased in the CA1 hippocampal region of subjects with schizophrenia. Schizophrenia Research, 2015, 166, 212-218.	2.0	27
31	Effects of antipsychotic medication on muscarinic M1 receptor mRNA expression in the rat brain. Journal of Neuroscience Research, 2008, 86, 457-464.	2.9	25
32	Luteolin, a natural flavonoid, inhibits methylglyoxal induced apoptosis via the mTOR/4E-BP1 signaling pathway. Scientific Reports, 2017, 7, 7877.	3.3	24
33	Neurodevelopmental Expression Profile of Dimeric and Monomeric Group 1 mGluRs: Relevance to Schizophrenia Pathogenesis and Treatment. Scientific Reports, 2016, 6, 34391.	3.3	23
34	Effects of common GRM5 genetic variants on cognition, hippocampal volume and mGluR5 protein levels in schizophrenia. Brain Imaging and Behavior, 2018, 12, 509-517.	2.1	22
35	Rethinking metabotropic glutamate receptor 5 pathological findings in psychiatric disorders: implications for the future of novel therapeutics. BMC Psychiatry, 2014, 14, 23.	2.6	21
36	Chronic treatment with simvastatin upregulates muscarinic M1/4 receptor binding in the rat brain. Neuroscience, 2008, 154, 1100-1106.	2.3	19

#	Article	IF	Citations
37	Cholesteryl ester levels are elevated in the caudate and putamen of Huntingtonâ€™s disease patients. Scientific Reports, 2020, 10, 20314.	3.3	18
38	Rapid cortico-limbic alterations in AMPA receptor densities after administration of PCP: Implications for schizophrenia. Journal of Chemical Neuroanatomy, 2008, 36, 71-76.	2.1	14
39	Perinatal PCP treatment alters the developmental expression of prefrontal and hippocampal muscarinic receptors. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2009, 33, 37-40.	4.8	14
40	Alterations of ubiquitin related proteins in the pathology and development of schizophrenia: Evidence from human and animal studies. Journal of Psychiatric Research, 2017, 90, 31-39.	3.1	11
41	Alterations in the kynurenine pathway and excitatory amino acid transporter-2 in depression with and without psychosis: Evidence of a potential astrocyte pathology. Journal of Psychiatric Research, 2022, 147, 203-211.	3.1	11
42	Opposing short- and long-term effects on muscarinic M1/4 receptor binding following chronic phencyclidine treatment. Journal of Neuroscience Research, 2007, 85, 1358-1363.	2.9	10
43	The long and the short of Huntingtonâ€™s disease: how the sphingolipid profile is shifted in the caudate of advanced clinical cases. Brain Communications, 2022, 4, fcab303.	3.3	10
44	Metabotropic glutamate receptor 5 in schizophrenia: emerging evidence for the development of antipsychotic drugs. Future Medicinal Chemistry, 2013, 5, 1471-1474.	2.3	9
45	GluN2B protein deficits in the left, but not the right, hippocampus in schizophrenia. BMC Psychiatry, 2014, 14, 274.	2.6	9
46	Prenatal methadone exposure impairs adolescent cognition and GABAergic neurodevelopment in a novel rat model of maternal methadone treatment. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 110, 110281.	4.8	9
47	A postmortem analysis of NMDA ionotropic and group 1 metabotropic glutamate receptors in the nucleus accumbens in schizophrenia. Journal of Psychiatry and Neuroscience, 2018, 43, 102-110.	2.4	9
48	Possibility of a sex-specific role for a genetic variant in FRMPD4 in schizophrenia, but not cognitive function. NeuroReport, 2016, 27, 33-38.	1.2	8
49	mGluR2/3 agonist LY379268 rescues NMDA and GABAA receptor level deficits induced in a two-hit mouse model of schizophrenia. Psychopharmacology, 2016, 233, 1349-1359.	3.1	7
50	N-Methyl- -Aspartate receptor and inflammation in dorsolateral prefrontal cortex in schizophrenia. Schizophrenia Research, 2022, 240, 61-70.	2.0	6
51	Exercise and yoga during pregnancy and their impact on depression: a systematic literature review. Archives of Women's Mental Health, 2022, 25, 539-559.	2.6	6
52	Alterations of p75 neurotrophin receptor and Myelin transcription factor 1 in the hippocampus of perinatal phencyclidine treated rats. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2015, 63, 91-97.	4.8	5
53	The effects of perinatal fluoxetine exposure on emotionality behaviours and cortical and hippocampal glutamatergic receptors in female Sprague-Dawley and Wistar-Kyoto rats. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 108, 110174.	4.8	4
54	Chronic Adolescent CDPPB Treatment Alters Short-Term, but not Long-Term, Glutamatergic Receptor Expression. Neurochemical Research, 2018, 43, 1683-1691.	3.3	3

#	Article	IF	Citations
55	Perinatal administration of phencyclidine alters expression of Lingo-1 signaling pathway proteins in the prefrontal cortex of juvenile and adult rats. Neuronal Signaling, 2018, 2, NS20180059.	3.2	3
56	Phospholipid Profiles Are Selectively Altered in the Putamen and White Frontal Cortex of Huntingtonâ€™s Disease. Nutrients, 2022, 14, 2086.	4.1	3
57	Effects of short- and long-term aripiprazole treatment on Group I mGluRs in the nucleus accumbens: Comparison with haloperidol. Psychiatry Research, 2018, 260, 152-157.	3.3	2
58	Increased translocator protein (TSPO) binding throughout neurodevelopment in the perinatal phencyclidine rodent model of schizophrenia. Schizophrenia Research, 2019, 212, 243-245.	2.0	2
59	Poster #S173 METABOTROPIC GLUTAMATE RECEPTOR 5 DYSREGULATION IN SCHIZOPHRENIA. Schizophrenia Research, 2014, 153, S152.	2.0	1
60	Could an allied health care approach reduce the unacceptable incidence of suicide after psychiatric hospital discharge?. Bipolar Disorders, 2018, 20, 403-404.	1.9	1
61	Effects of GRASP variation on memory in psychiatrically healthy individuals and cognitive dysfunction in schizophrenics. Gene Reports, 2017, 6, 121-127.	0.8	0